BUZZ-英国接受罕见肺病药物申请,萨瓦拉公司股价上涨

路透中文
Apr 07
BUZZ-英国接受罕见肺病药物申请,萨瓦拉公司股价上涨

4月7日 - ** 生物技术公司萨瓦拉SVRA.O股价盘前上涨2%至5.70美元

** 该公司称英国药品监管机构已接受Molbreevi治疗自身免疫性肺泡蛋白病的申请

** 这种罕见的肺病会导致气囊内物质堆积,使患者呼吸困难

** 公司表示,英国监管机构将加速审查该药物,预计将于2026年第四季度做出决定

** 称 Molbreevi 是一种吸入式药物,旨在帮助肺部清除堆积物

** 公司称,美国和欧洲也在对该药物进行审查,美国食品及药物管理局将于2026年8月采取行动,欧盟预计将于2027年第一季度做出决定

** 截至上一交易日收盘,股价年累计下跌约 7%

(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10